Ceragenix and MAST BioSurgery Enter into Joint Development Agreement for New Antimicrobial Surgical Products

DENVER--(Business Wire)--
Ceragenix Pharmaceuticals, Inc. ("Ceragenix") (OTCBB:CGXP), a medical device
company focused on infectious disease and dermatology, today announced that it
has entered into a Joint Development Agreement ("JDA") with MAST BioSurgery Inc.
("MAST") for the development of one or more new surgical products incorporating
Ceragenix`s CeraShield antimicrobial technology. Under the terms of the JDA,
MAST will have exclusive rights to develop specified products and negotiate
commercialization terms for such products for a period of six months. This is
the first joint development and exclusive option to license entered into by
Ceragenix for a medical device application of its CeraShield antimicrobial
technology.

Mr. Steven Porter, Chairman and CEO of Ceragenix said: "We're very pleased to
announce our first joint development agreement involving our CeraShield
antimicrobial coating related technologies for long term protection of
in-dwelling medical devices with an innovative surgical medical device firm like
MAST BioSurgery. It is our expectation that we will enter into several other
similar agreements for different devices during the remainder of 2009."

Count Lukas Bluecher, Co-Founder of MAST AG, Switzerland, and CEO of MAST Inc
USA, said: "We are thrilled about the opportunity to combine our product line
with the highly innovative CeraShield antimicrobial agent and are greatly
looking forward to our joint efforts and further cooperation."

About Ceragenix

Ceragenix Pharmaceuticals, Inc. is a medical device company focused on
infectious disease and dermatology. The Company has two base technology
platforms; Ceragenins for treatment of infectious disease and Barrier Repair for
the treatment of dermatological disorders including atopic dermatitis, neonatal
skin disorders and others. Ceragenin compounds are active against a broad range
of gram positive and negative bacteria. We have used our Ceragenin technology to
formulate Cerashield antimicrobial coatings for medical devices. All Ceragenin
and Cerashield products are currently in the developmental stage. Ceragenix's
patented Barrier Repair technology, invented by Dr. Peter Elias, is the platform
for the development of EpiCeram which is currently being marketed by Promius
Pharmaceuticals (a wholly owned subsidiary of Dr. Reddy`s Laboratories) in the
United States under an exclusive supply and distribution agreement. For
additional information on Ceragenix, please visit www.ceragenix.com.

About Mast

MAST Biosurgery, Inc. is a wholly owned subsidiary of privately held MAST
Biosurgery AG. MAST Biosurgery, Inc. was founded in 2004 in San Diego, Calif.,
and is an industry leader in the design, development and production of
bioresorbable thin film implants for use in a wide variety of surgical
specialties. For more information about MAST Biosurgery, Inc., please visit
www.mastbio.com.

FORWARD LOOKING STATEMENTS FOR CERAGENIX.

This press release may contain forward-looking statements. These forward-looking
statements are subject to risks and uncertainties that may cause actual results
to differ materially from those expressed or implied by such forward-looking
statements, including, but not limited to, the following: the ability of MAST to
successfully develop a product using the Cerashield technology, the ability of
MAST and the Company to successfully negotiate license terms if a product is
successfully developed by MAST, the ability of the Company to raise sufficient
capital to finance its operations and planned activities including completing
development of its Ceragenin technology; the ability of the Company to meet its
obligations under the supply and distribution agreement with Dr. Reddy`s
Laboratories including having sufficient working capital to fulfill purchase
orders within the timeframes required by the agreement; the ability of the
Company to service its outstanding convertible debt obligations; receiving the
necessary marketing clearance approvals from the United States Food and Drug
Administration (the "FDA"); successful clinical trials of the Company`s planned
products including the ability to enroll the studies in a timely manner, patient
compliance with the study protocol, and a sufficient number of patients
completing the studies; the ability of the Company to commercialize its planned
products; the ability of the Company to successfully manufacture its products in
commercial quantities (through contract manufacturers); market acceptance of the
Company`s planned products, the Company`s ability to successfully develop its
licensed compounds, alone or in cooperation with others, into commercial
products, the ability of the Company to successfully prosecute and protect its
intellectual property, general economic conditions in the United States and
elsewhere, and the Company`s ability to hire, manage and retain qualified
personnel. The aforementioned factors do represent an all inclusive list. Actual
results, performance or achievements could differ materially from those
contemplated, expressed or implied by the forward-looking statements contained
in this press release. In particular important factors that could cause actual
results to differ materially from our forward-looking statements including
general economic factors, business strategies, the state of capital markets,
regulatory conditions, and other factors not currently known to us, may be
significant, now or in the future, and the factors set forth in this press
release may affect us to a greater extent than indicated. All forward-looking
statements attributable to us or persons acting on our behalf are expressly
qualified in their entirety by the cautionary statements set forth in this press
release and in other documents that we file from time to time with the
Securities and Exchange Commission includingits Annual Report on Form 10-K for
the year ended December 31, 2008,Quarterly Reports on Form 10-Q and Current
Reports on Form 8-K to be filed in 2009. Except as required by law, we do not
undertake any obligation to update any forward-looking statement, whether as a
result of new information, future events or otherwise.

Ceragenix Pharmaceuticals, Inc.
Steven Porter, +1-720-946-6440
Chairman and CEO
or
MAST Biosurgery AG
Count Lukas Bluecher, Co-Founder of MAST AG, CEO of MAST Inc. USA
Alfred Munch, Director
41-43-817-6550

Copyright Business Wire 2009